GLD ETF Gains 0.7%
Dow Jones2026/10/08 20:35This article was automatically generated using Dow Jones technology. Shares of SPDR Gold Shares advanced 0.7% to $378.62 Thursday on what proved to be an overall unfavorable trading session for the U.S. stock market, with the S&P 500 Index falling 0.5% to 7,765.36. The ETF's shares closed 25.7% below the 52-week high of $509.70 seen on January 29, 2026. Trading volume was 9,479,323, compared to the 65-day average trading volume of 9,163,310. As of October 7, the fund's net asset value totaled $375.43 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:35 ET (20:35 GMT)
This article was automatically generated using Dow Jones technology.
Shares of SPDR Gold Shares advanced 0.7% to $378.62 Thursday on what proved to be an overall unfavorable trading session for the U.S. stock market, with the S&P 500 Index falling 0.5% to 7,765.36.
The ETF's shares closed 25.7% below the 52-week high of $509.70 seen on January 29, 2026.
Trading volume was 9,479,323, compared to the 65-day average trading volume of 9,163,310.
As of October 7, the fund's net asset value totaled $375.43 per share.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 08, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
